MOTS-c

Safety Profile of MOTS-c

Evidence Limitations

The safety profile of MOTS-c in humans is not well-established based on available evidence. Current research consists primarily of preclinical studies and observational research. Only one Phase 2 clinical trial (NCT07505745) for insulin sensitivity is currently recruiting participants, indicating limited human safety data.

Known Side Effects

No specific adverse effects from MOTS-c administration have been documented in the available literature. The research focuses predominantly on potential therapeutic benefits rather than safety outcomes.

Contraindications and Precautions

Specific contraindications for MOTS-c have not been established due to insufficient clinical data. However, based on the limited research available:

• One study noted that MOTS-c "blunts reparative function in human mesenchymal stromal cells," suggesting potential interference with tissue repair mechanisms
• The clinical significance of this finding for human health remains unclear

Drug Interactions

No drug interactions with MOTS-c have been identified or studied in the available evidence.

Populations That Should Exercise Caution

Without comprehensive clinical trial data, it is not possible to identify specific populations who should avoid MOTS-c. The ongoing clinical research includes studies in:

• Adults with prediabetes and overweight/obesity
• Patients undergoing renal transplantation
• Individuals with type 2 diabetes and coronary artery disease

Clinical Monitoring Considerations

Given the research focus on metabolic and cardiac effects, monitoring of cardiovascular and metabolic parameters may be warranted, though specific protocols have not been established.

Disclaimer

This information is for educational purposes only and should not be used as a substitute for professional medical advice. The safety profile of MOTS-c remains largely unknown due to limited human clinical data. Consult with a healthcare provider before considering any experimental treatments.